期刊文献+

2-甲氧基雌二醇缓控释制剂的体外释药研究

The Study on Release Characteristics of 2-methoxyestradiol in Vitro of Targeted Delivery System
下载PDF
导出
摘要 目的考察2-甲氧基雌二醇缓控释制剂的体外释药情况。方法按照2010年版《中华人民共和国药典》规定的第一法,分别在p H 7.4及p H 5.5的释药介质中考察2-甲氧基雌二醇缓控释制剂的体外释药情况。结果在p H 7.4及p H 5.5释药介质中,与2-甲氧基雌二醇溶液对照组相比,所制备缓控释制剂均显示出缓释效果且在p H 5.5释药介质中释药相对较快。结论制备的制剂具有缓控释特性及对肿瘤靶部位的选择性。 Objective Study the release characteristics of 2-methoxyestradio in vitro of targeted delivery system. Methods According to the first method of the"pharmacopoeia of the People's Republic of China"(2010). In vitro drug release were carried out in the p H 7.4 and p H 5.5 dissolution medium. Results Compared with the control group,the preparation released slowly and released quickly relatively in p H 5.5 dissolution medium. Conclusion The preparation has a sustained release characteristic and tissue targeting selectively in tumour.
作者 李艳凤
出处 《中国卫生标准管理》 2015年第32期136-137,共2页 China Health Standard Management
关键词 2-甲氧基雌二醇 缓控释 体外释药 2-methoxyestradio Sustained and controlled release Drug release in vitro
  • 相关文献

参考文献3

二级参考文献74

  • 1Axelrod LR, Rao PN, Goldzieher JW. The conversion of 2- hydroxyestradiol-1715 to 2-hydroxy and 2-methoxy metabo- lites in human urine[ J]. Arch Biochem Biophys,1961,94: 265.
  • 2Sutherland TE, Anderson RL, Hughes RA, et al. 2-Me- thoxyestradiol : a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents [ J ]. Drug Discov Today, 2007,12(13/14) :577.
  • 3Yue TL,Wang X, Louden CS, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression [ J ]. Mol Pharmacol, 1997,51 ( 6 ) :951.
  • 4Sweeney C, Liu G,Yiannoutsos C, et al. A phase Ⅱ muhi- center, randomized, double blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone refractory prostate cancer [ J ]. Clin Cancer Res, 2005,11 ( 18 ) :6625.
  • 5Desai GH, Mallery SR,Schwendeman S. Effect of formula- tion parameters on 2-methoxyestradiol release from inject- able cylindrical poly ( DL-lactide-co-glycolide ) implants [J]. Eur J Pharm Biopharm,2008,70( 1 ) :187.
  • 6Kawaguchi E,Shimokawa K, Ishii F. Physicochemical prop- erties of structured phosphatidylcholine in drug carrier lipid emulsions for drug delivery systems [ J ]. Colloids Surf B Biointerfaces, 2008,62 ( 1 ) : 130.
  • 7Cuellar I, Bullon J, Forgarini AM. More efficient prepara- tion of parenteral emulsions or how to improve a pharma- ceutical recipe by formulation [ J ]. Chem Enginee Sci, 2005,60(7) :2127.
  • 8Muller RH, Schmidt S, Buttle I, et al. SolEmuls-novel technology for the formulation of i. v. Emulsions with poor- ly soluble drugs [ J ]. Int J Pharm, 2004,269 ( 2 ) :293.
  • 9张玉全,张振中.2-甲氧基雌二醇静脉纳米乳剂的制备方法:中国,200810049466.5[P].2010-06-18.
  • 10Zhao, Q.; Han, B.; Wang, Z.; Gao, C.; Peng, C.; Shen, J. Nanomedicine, 2007, 3(1): 63.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部